Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of GoodwillAmortization of GoodwillAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt repayments
Ratios

Avanos Medical (AVNS) Long-Term Debt Repayments (2013 - 2019)

Avanos Medical recorded quarterly Long-Term Debt Repayments of $200000.0 in Q3 2019, little changed quarter-over-quarter from $200000.0 in Q2 2019.

Avanos Medical's Long-Term Debt Repayments history runs 4 years deep, the most recent figure standing at $200000.0 for Q3 2019.

  • In Q3 2019, Long-Term Debt Repayments changed N/A year-over-year to $200000.0; the TTM figure through Dec 2019 stood at $400000.0 (changed N/A YoY), while the FY2023 annual figure was $4.7 million, down 96.29% from the prior year.
  • Long-Term Debt Repayments came in at $200000.0 for Q3 2019 at Avanos Medical, roughly flat from $200000.0 in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $50.0 million in Q2 2015 to a low of $200000.0 in Q2 2019.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Repayments (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 1.42 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn 1.00 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -
10 Avanos Medical 1.17 Bn 1.10 Bn 94.20 Mn -

Historic Data

Download Data 🔒
DateValue
Sep 30, 2019 200,000.00
Sep 30, 2019 200,000.00
Jun 30, 2019 200,000.00
Jun 30, 2019 200,000.00
Jun 30, 2015 50.00 Mn
Jun 30, 2015 50.00 Mn
Mar 31, 2015 1.00 Mn
Mar 31, 2015 1.00 Mn
Dec 31, 2014 10.90 Mn
Dec 31, 2014 10.90 Mn
Mar 31, 2014 2.90 Mn
Mar 31, 2014 2.90 Mn
Dec 31, 2013 15.20 Mn
Dec 31, 2013 15.20 Mn